Ascentage Pharma Group International (HKG:6855) reported a net loss attributable to shareholders of 590.8 million yuan for the first half of 2025, compared with a profit of 163.0 million yuan a year earlier.
Loss per share was 1.73 yuan, compared with earnings per share of 0.55 yuan a year earlier.
Revenue fell 71.6% to 233.7 million yuan, compared with 823.7 million yuan in the prior-year period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.